Skip to main content
eScholarship
Open Access Publications from the University of California

Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice

  • Author(s): Silber, BM
  • Rao, S
  • Fife, KL
  • Gallardo-Godoy, A
  • Renslo, AR
  • Dalvie, DK
  • Giles, K
  • Freyman, Y
  • Elepano, M
  • Gever, JR
  • Li, Z
  • Jacobson, MP
  • Huang, Y
  • Benet, LZ
  • Prusiner, SB
  • et al.

Published Web Location

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640342/
No data is associated with this publication.
Abstract

Purpose: To discover drugs lowering PrPScin prion-infected cultured neuronal cells that achieve high concentrations in brain to test in mouse models of prion disease and then treat people with these fatal diseases. Methods: We tested 2-AMT analogs for EC50and PK after a 40 mg/kg single dose and 40-210 mg/kg/day doses for 3 days. We calculated plasma and brain AUC, ratio of AUC/EC50after dosing. We reasoned that compounds with high AUC/EC50ratios should be good candidates going forward. Results: We evaluated 27 2-AMTs in single-dose and 10 in 3-day PK studies, of which IND24 and IND81 were selected for testing in mouse models of prion disease. They had high concentrations in brain after oral dosing. Absolute bioavailability ranged from 27-40%. AUC/EC50ratios after 3 days were >100 (total) and 48-113 (unbound). Stability in liver microsomes ranged from 30->60 min. Ring hydroxylated metabolites were observed in microsomes. Neither was a substrate for the MDR1 transporter. Conclusions: IND24 and IND81 are active in vitro and show high AUC/EC50ratios (total and unbound) in plasma and brain. These will be evaluated in mouse models of prion disease. © 2013 Springer Science+Business Media New York.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item